Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Ella X. Du"'
Autor:
Jeffrey S. Weber, Tayla Poretta, Brian D. Stwalley, Leon A. Sakkal, Ella X. Du, Travis Wang, Yan Chen, Yan Wang, Keith A. Betts, Alexander N. Shoushtari
Publikováno v:
Cancer Immunology, Immunotherapy. 72:945-954
Background Recurrence-free survival (RFS) and overall survival (OS) data for adjuvant nivolumab versus placebo (proxy for routine surveillance) in patients with high-risk, resected melanoma are lacking. This post hoc, indirect treatment comparison (I
Autor:
Bradley McGregor, Daniel M. Geynisman, Mauricio Burotto, Cristina Suárez, Maria T. Bourlon, Pedro C. Barata, Shuchi Gulati, Stephen Huo, Flavia Ejzykowicz, Steven I. Blum, Viviana Del Tejo, Melissa Hamilton, Jessica R. May, Ella X. Du, Aozhou Wu, Pavol Kral, Cristina Ivanescu, Andi Chin, Keith A. Betts, Chung-Han Lee, Toni K. Choueiri, David Cella, Camillo Porta
Publikováno v:
European Urology Oncology.
Autor:
Bradley McGregor, Daniel M Geynisman, Mauricio Burotto, Camillo Porta, Cristina Suarez, Maria T Bourlon, Viviana Del Tejo, Ella X Du, Xiaoran Yang, Selvam R Sendhil, Keith A Betts, Stephen Huo
Publikováno v:
Scientia
Background Despite 4 approved combination regimens in the first-line setting for advanced renal cell carcinoma (aRCC), adverse event (AE) costs data are lacking. Materials and Methods A descriptive analysis on 2 AE cost comparisons was conducted usin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24a1624d6b56737a87630493fac99671
https://hdl.handle.net/11351/9391
https://hdl.handle.net/11351/9391
Autor:
Daniel M, Geynisman, Ella X, Du, Xiaoran, Yang, Selvam R, Sendhil, Viviana Del, Tejo, Keith A, Betts, Stephen, Huo
Publikováno v:
Future Oncology. 18:1219-1234
Aims: To assess grade 3/4 adverse events (AEs) and costs of first-line nivolumab plus ipilimumab versus sunitinib in advanced or metastatic renal cell carcinoma. Methods: Individual patient data from the all treated population in the CheckMate 214 tr
Autor:
Jeffrey S, Weber, Tayla, Poretta, Brian D, Stwalley, Leon A, Sakkal, Ella X, Du, Travis, Wang, Yan, Chen, Yan, Wang, Keith A, Betts, Alexander N, Shoushtari
Publikováno v:
Cancer immunology, immunotherapy : CII.
Recurrence-free survival (RFS) and overall survival (OS) data for adjuvant nivolumab versus placebo (proxy for routine surveillance) in patients with high-risk, resected melanoma are lacking. This post hoc, indirect treatment comparison (ITC) used po
Autor:
Daniel M. Geynisman, Mauricio Burotto, Camillo Porta, Cristina Suarez, Maria T. Bourlon, Stephen Huo, Viviana Del Tejo, Ella X. Du, Xiaoran Yang, Keith A. Betts, Toni K. Choueiri, Bradley McGregor
Publikováno v:
Scientia
Advanced Renal Cell Carcinoma; Adverse Events; Nivolumab Carcinoma de células renales avanzado; Eventos adversos; Nivolumab Carcinoma de cèl·lules renals avançat; Esdeveniments adversos; Nivolumab Background and Objectives Novel immunotherapy-bas
Autor:
Namita Tundia, Ruta Sawant, Ella X Du, Keith A. Betts, Yan Song, Patrick Tang, Janet E. Pope, Cynthia Z. Qi
Publikováno v:
Advances in Therapy
Autor:
Pedro C. Barata, Ella X. Du, Hongbo Yang, Chunyi Xu, Helen Guo, Caroline Cui, Jonathan Nazari, Alexander Niyazov
Publikováno v:
Journal of Clinical Oncology. 41:95-95
95 Background: Contemporary rw data is needed to describe the heterogeneity of the tx landscape among diverse pt populations. This study assessed rw tx patterns and clinical outcomes among US pts receiving tx for mCRPC. Methods: Data from pts with mC
Autor:
Pedro C. Barata, Ella X. Du, Hongbo Yang, Chunyi Xu, Helen Guo, Caroline Cui, Jonathan Nazari, Alexander Niyazov
Publikováno v:
Journal of Clinical Oncology. 41:97-97
97 Background: There is a paucity of evidence that evaluates the impact of HRR mutation status on clinical outcomes in pts with mCRPC. This study assessed the real-world (rw) progression-free survival (rwPFS) based on HRR mutation status (HRR mutated
Publikováno v:
Rheumatology and Therapy
Introduction Upadacitinib and tofacitinib are Janus kinase inhibitors approved for moderate-to-severe rheumatoid arthritis (RA). In the absence of head-to-head trials comparing their effectiveness, this study assessed the efficacy of upadacitinib 15